3 recruiting, 2 completed, 1 active not recruiting, 1 withdrawn. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Recruiting 3, Completed 2, Active not recruiting 1, Withdrawn 1 |
Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer Bevacizumab - Solid Tumor | Phase 4 | Recruiting | Hebei Medical University Fourth Hospital | 75 | 2022-03-31 | 2025-12-11 |
| Propofol vs Sevo for Paediatric Tumor Surgery propofol, sevoflurane - Solid Tumor, Carcinoma | Phase 4 | Recruiting | Hong Kong Children's Hospital | 100 | 2021-01-11 | 2022-03-16 |
| Durvalumab Long-Term Safety and Efficacy Study Durvalumab - Solid Tumor | Phase 4 | Completed | AstraZeneca | 163 | 2019-09-05 | 2024-12-20 |
| Dabrafenib and/or Trametinib Rollover Study dabrafenib, trametinib - Melanoma, Non Small Cell Lung Cancer | Phase 4 | Recruiting | Novartis Pharmaceuticals | 100 | 2018-01-26 | 2026-11-10 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin | Phase 4 | Active not recruiting | Pharmacyclics Switzerland GmbH | 297 | 2017-05-22 | 2025-10-30 |
| Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease denosumab, pamidronate - Solid Tumor, Metastatic Bone Disease | Phase 4 | Withdrawn | Amgen | 2014-11-01 | 2015-02-18 | |
| Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype CPT-11, Raltegravir (Isentress®), Midazolam - Solid Tumor | Phase 4 | Completed | National University Hospital, Singapore | 25 | 2010-04-01 | 2012-11-01 |
Carcinoma, Non-Small-Cell Lung (2) · Bone Diseases (1) · Carcinoma (1) · Glioma (1) · Graft vs Host Disease (1) · Leukemia, B-Cell (1) · Lung Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Neoplasms (1) · Neoplastic Cells, Circulating (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1)
Bevacizumab (1) · Denosumab (1) · Irinotecan (1) · Midazolam (1) · Pamidronate (1) · Propofol (1) · Raltegravir Potassium (1) · Sevoflurane (1) · dabrafenib (1) · durvalumab (1) · ibrutinib (1) · trametinib (1)
Amgen (1) · AstraZeneca (1) · Hebei Medical University Fourth Hospital (1) · Hong Kong Children's Hospital (1) · National University Hospital, Singapore (1) · Novartis Pharmaceuticals (1) · Pharmacyclics Switzerland GmbH (1)
Canada (3) · Czechia (3) · France (3) · Hungary (3) · Russia (3) · Spain (3) · United States (3) · Argentina (2) · Australia (2) · China (2) · Germany (2) · Japan (2) · Netherlands (2) · Poland (2) · South Korea (2)
Boon Cher Goh, MRCP (1) · Jared Weiss, MD (1) · Kevin Wu (1) · Sau Man Lee, MBBS (1)
2016 (1), 2019 (1), 2023 (1)